PRS 080
Alternative Names: PRS 080#022-DP; PRS-080Latest Information Update: 29 Apr 2020
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals
- Class Antianaemics; Lipocalins
- Mechanism of Action Hepcidin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Iron deficiency anaemia
Most Recent Events
- 20 Jan 2020 ASKA Pharmaceutical decides not to exercise its option to license PRS 080 in Japan, South Korea and other Asian countries excluding China
- 31 Dec 2019 Discontinued - Phase-II for Iron deficiency anaemia in Czech Republic, Germany (IV)
- 16 Jun 2019 Pieris Pharmaceuticals completes a phase II trial in Iron deficiency anaemia in Czech Republic, Germany (IV) (NCT03325621)